Retatrutide is a triple agonist acting on GLP-1, GIP and glucagon receptors.
Retatrutide is a triple agonist acting on GLP-1, GIP and glucagon receptors. Studied for significant weight reduction in clinical trials. Newer than semaglutide and tirzepatide.
In research, Retatrutide is studied for significant weight reduction in clinical trials. newer than semaglutide and tirzepatide. researched for appetite regulation and metabolic effects. a next-generation incretin research compound.
Research-grade Retatrutide should come with batch-specific third-party testing and a Certificate of Analysis (CoA) confirming purity. Woosh Labs supplies Retatrutide for research purposes only, third-party tested to 99%+ purity with a CoA on every order.
In research, Retatrutide is often studied alongside Tesamorelin. Both should be verified with a CoA before use in a research setting.
Educational and research information only. Not medical advice; no dosing guidance. Retatrutide is supplied for research purposes only. Store: wooshlabs.com.